At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 40 enrolled
Drug / intervention
dexamethasone implantdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Ozurdex for Retinal Vein Occlusion Study (ORVO Study)
In Brief
A Phase 3 clinical trial evaluating dexamethasone implant for Retinal Vein Occlusion. Completed, enrolled 40 participants across 1 site.
Detailed Summary
To measure the pro-permeability factors in the aqueous humor of patients with persistent/recurrent macular edema after an injection of Ozurdex.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsRetinal Vein Occlusion
CountriesUnited States
CollaboratorsAllergan
Timeline
Phase 3CompletedFinished
20132014201520162017201820192020202120222023202420252026
Enrollment StartFeb 2013
First PostedFeb 2013
Primary CompletionDec 2014
TodayJul 2026
First PostedFeb 13, 2013
Enrollment StartFeb 1, 2013
Primary CompletionDec 1, 2014
TodayJul 2, 2026
Enrollment to primary: 1.8 yearsPosted 13.4 years ago
Interventions
dexamethasone implantdrug